Floatz logo

Zoledronate

Bone, Metastatic Cancer

Kelly Fitzgerald, MDSmall moleculePhase 3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Bone, Metastatic Cancer cohort.

Asset / SponsorPhaseRating
Denosumab
Kelly Fitzgerald, MD
Phase 2CCC
Ibandronate
Kelly Fitzgerald, MD
Phase 2CCC

Same molecule, other indications

Zoledronate is also rated in:

metastatic carcinoma in the boneDormant
BBB
Indicative ·
79 / 100
View asset →
osteoporosisDormant
BBB
Indicative ·
76 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →